Semaglutide and tirzepatide are showing strong efficacy against alcohol, nicotine, and opioid addiction in early trials.
Editorial desk for The Spec'd — technology coverage at full resolution. Published by Hyphn Media Inc., Toronto.
DeepMind's structure prediction tool has been used in 2 million research projects.
Semaglutide's primary patents expire between 2026 and 2031, opening the market to biosimilars.
After COVID mRNA vaccines, Moderna and Pfizer have completed Phase 3 trials for influenza with substantially better efficacy.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Leave a Reply